NCT03097211View on ClinicalTrials.gov

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2006

Primary Completion Date

October 20, 2006

Study Completion Date

October 20, 2006

Conditions

Parkinson Disease

Interventions

DRUG

Placebo

Placebo capsules. Orally, with 240 mL of potable water.

DRUG

BIA 6-512

The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.

DRUG

Madopar® 250

Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.

DRUG

Nebicapone

Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.

Trial Locations (1)

4745-457

Human Pharmacology Unit (UFH) - BIAL - Portela & Cª, SA, S. Mamede Do Coronado

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT03097211 - Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg | Biotech Hunter | Biotech Hunter